Regulatory Analysis of Vimentin Expression in Metastatic Versus Nonmetastatic Breast Cancer Cell Lines by Bird, Danielle N.
Virginia Commonwealth University
VCU Scholars Compass
Theses and Dissertations Graduate School
1994
Regulatory Analysis of Vimentin Expression in
Metastatic Versus Nonmetastatic Breast Cancer
Cell Lines
Danielle N. Bird
dnbird@hotmail.com
Follow this and additional works at: http://scholarscompass.vcu.edu/etd
Part of the Biochemistry Commons
© The Author
This Thesis is brought to you for free and open access by the Graduate School at VCU Scholars Compass. It has been accepted for inclusion in Theses
and Dissertations by an authorized administrator of VCU Scholars Compass. For more information, please contact libcompass@vcu.edu.
Downloaded from
http://scholarscompass.vcu.edu/etd/4366
Virginia Commonwealth University 
School ofMedicine 
This is to certify that the thesis prepared by Danielle N. Bird entitled "Regulatory 
Analysis ofVimentin Expression in Metastatic Versus Nonmetastatic Breast Cancer Cell 
Lines" has been approved by her committee as satisfactory completion of the thesis 
requirement for the degree of Master of Science. 
Zendra E. Zehner, Ph.D., Director of Thesis 
REGULATORY ANALYSIS OF VIMENTIN EXPRESSION IN 
METASTATIC VERSUS NONMETASTATIC BREAST CANCER CELL 
LINES 
A Thesis submitted in partial fulfillment of the 
requirements for the degree of Master of Science 
at Virginia Commonwealth University 
By 
Danielle N. Bird 
B.A. Johns Hopkins University 
May, 1993 
Director: Dr. Zendra E. Zehner 
Associate Professor 
Department of Biochemistry and Molecular 
Biophysics 
Virginia Commonwealth University 
Richmond, Virginia 
August, 1994 
ii 
Acknowledgement 
I would like to thank all of those who helped make this 
possible: Dr. Zehner for her guidance, suggestions, and 
patience; my co-workers in the lab: Alma, Ann-Alyssa, 
Brent, Will, and especially Indira, who taught me all the 
procedures and put up with my dad taking pictures; my 
committee members Dr. Roesser and Dr. Ware, for their wise 
counsel; and for his initial encouragement to begin this 
j ourney and continued support throughout, Dr. Holmes. 
Also, thanks to my family: Mom, for the unfailing 
encouragement; Dad, for his advice and help with 
spreadsheets; and Derek, for the great phone conversations 
that helped me keep my sense of humor. And, to Rob, thank 
you for the graphical assistance and a wonderful friendship. 
Table of Contents 
List of Figures ........ . 
List of Abbreviations .. 
Abstract ....... . 
Introduction ......................... . 
Intermediate Filament Proteins .......... . 
Intermediate Filament Protein Structure .. 
Intermediate Filament Protein Assembly .. 
Eukaryotic Transcription ............. . 
Eukaryotic Transcription Regulation .. . 
Promoters .. . 
Enhancers ....... . 
Repressors ...... . 
Antirepressors ........................ . 
Regulation of Chicken Vimentin ........ . 
Breast Cancer ........................ . 
Vimentin Expression in Breast Cancer .. 
Rationale ............................ . 
Materials and Methods .. 
Plasmid Preparation .... 
iii 
Page 
. .v 
.vi 
. ... vii 
. . .  1 
. . . .  2 
. . .  3 
. . .  4 
. . .  6 
. . .  8 
. . . .  8 
. . .  10 
.11 
. .12 
. .12 
. .  21 
. . 22 
. . .  27 
. . .  29 
. . .  29 
Sequencing...................................... . . . .  29 
Cell Culture, DNA Transfections, and CAT Assays . .... 29 
Nude Mouse Assay and Invasive Assay............. .32 
Results ........................... . 
DNA Transfections. 
MDA Data ......... . 
.33 
.33 
.33 
iv 
MCF-7 Data . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  39 
Nude Mouse Assay . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  42 
Discussion . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  43 
Bibliography . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  50 
Vita . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .  55 
v 
List of Figures 
Figure Page 
1 Model of the Regulatory Elements of the Chicken and 
Human Vimentin Gene ................................ 15 
2 Comparison of Chicken and Human Sequences. 
3 Northern and Southwestern Blot Analyses of Two 
Different Breast Cancers ................. . 
4 Transient Transfections of Various Chicken 
Vimentin 5'-end CAT Constructs in 
.. 20 
. ..... 26 
MDA-MB-231 Cells (1) ............................... 35 
5 Transient Transfections of Various Chicken 
Vimentin 5'-end CAT Constructs in 
MDA-MB-231 Cells (2) ............................... 38 
6 Transient Transfections of Various Chicken 
Vimentin 5'-end CAT Constructs in 
MCF-7 Cells ........................................ 41 
bp 
CaP04 
CAT 
DMEM 
cpm 
HBSS 
IF 
IFP 
kb 
kDa 
M 
MDA 
MEM 
p 
pol II 
pg 
pm 
!lg 
Il  
List of Abbreviations 
base pair 
calcium phosphate 
chloramphenicol acetyltransferase 
Dulbecco's Modified Eagle Medium 
counts per minute 
Hanks' Balanced Salt Solution 
intermediate filament 
intermediate filament protein 
kilobase 
kilodalton 
molar 
MDA-MB-231 
Minimum Essential Medium 
plasmid 
eukaryotic RNA polymerase II 
picogram 
picomole 
microgram 
microliter 
vi 
ABSTRACT 
REGULATORY ANALYSIS OF VIMENTIN EXPRESSION IN METASTATIC 
VERSUS NON-METASTATIC BREAST CANCER CELL LINES 
By Danielle Nichole Bird, B.A. 
A thesis submitted in partial fulfillment of the 
requirements for the degree of Master of Science at Virginia 
Commonwealth University. 
Virginia Commonwealth University, 1994. 
Major Director: Dr. Zendra E. Zehner, Ph.D. 
Associate Professor 
Department of Biochemistry and Molecular 
Biophysics 
The intermediate filament gene family, composed of six 
classes, shows both tissue and development-specific 
expression. Vimentin is a unique member of the intermediate 
filament protein family: although it is expressed in cells 
of mesenchymal origin, vimentin may also be expressed with 
other intermediate filament proteins during early stages of 
development. In some cases, as differentiation continues, 
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vimentin is normally down-regulated whereas other 
intermediate filament proteins, like desmin, glial 
fibrillary acidic protein, or neurofilaments are turned on 
in muscle, glial cells, or neurons, respectively. In some 
metastatic cancers, including breast and prostate cancers, 
vimentin is aberrantly expressed, despite the embryonic 
origin of the metastatic cell. From a Northern analysis 
(Thompson et al., 1992; Stover et al., 1994), it was 
determined that vimentin mRNA is highly abundant in the 
metastatic breast carcinoma cell line, MDA-MB-231, while in 
the nonmetastatic breast carcinoma cell line, MCF-7, no 
vimentin mRNA is present. 
A central question to metastasis is, how is the 
vimentin gene expressed in the metastatic but not the 
nonmetastatic cancer cell? Several cis-acting elements 
localized to the 5'-end of the chicken vimentin gene and 
trans-acting factors important in the regulation of vimentin 
gene expression have been identified. By sequence homology, 
comparable elements can be found in the human vimentin gene. 
Most notable of these is a unique silencer element and an 
overriding element, referred to as an antisilencer. These 
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elements bind a 90 kDa and 120 kDa protein, respectively, in 
chicken, mouse, and human nuclear extracts. Previously, the 
silencer factor was found to be missing in nuclear extracts 
from a metastatic breast cancer cell line MDA-MB-231 but 
abundant in the nonmetastatic counterpart MCF-7 (Stover et 
al., 1994). The antisilencer exhibits the opposite pattern. 
Here, various combinations of these elements have been fused 
to the bacterial chloramphenicol acetyltransferase reporter 
gene, CAT. Transcriptional activity was then compared in the 
different breast cancer cell lines in order to try and 
understand how vimentin is expressed in the metastatic but 
not the nonmetastatic cancer cell. 
INTRODUCTION 
The goal of this thesis is to examine the expression 
patterns of various regulatory regions from the chicken 
vimentin gene in metastatic versus nonmetastatic human 
breast cancers. Specifically, functional activity will be 
analyzed in MDA-MB-231 cells, which express vimentin, and in 
MCF-7 cells, which do not express vimentin. By using various 
combinations of the 5'-end regulatory regions, it may be 
possible to conclude which region(s) is responsible for 
controlling the aberrant expression of vimentin in the MDA 
cell line. To fully understand this project, several issues 
need to be addressed. These include the differences in the 
two cell lines chosen for this study and the regulatory 
regions in the 5'-end of the vimentin gene that have been 
thus far characterized. Also, an overview of the expression 
pattern of the vimentin protein, transcriptional processes, 
and the intermediate filament protein (IFP) family will 
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complete the discussion. Since this study is concerned with 
the regulation of the IFP vimentin, it is appropriate to 
begin with a description of intermediate filaments (IF}. 
Intermediate Filament Proteins 
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The cytoskeleton of cells is composed of three types of 
filaments: microtubules (25 nm in diameter}, intermediate 
filaments (11 nm in diameter}, and microfilaments (6 nm in 
diameter}. Of these, the intermediate filament proteins 
(IFPs} are the major component of this network and serve 
several functions. They are believed to anchor the cell's 
organelles, including the nucleus, as well as to maintain 
compartmentalization and possibly communication within the 
cell (Steinert and Roop, 1988; Steinert and Liem 1990} 
Vimentin belongs to one of six different IF gene 
classes. These classes include: acidic keratins (Type I}, 
neutral-basic keratins (Type II}, vimentin, desmin and glial 
fibrillary acidic proteins (Type III}, neurofilaments (Type 
IV}, lamins (Type V}, and nestins (Type VI} (Steinert and 
Roop, 1988; Lendahl et al., 1990}. 
In general, the IFs have been found to be tissue-
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specific and developmentally regulated. Vimentin is unique 
in that it deviates from the normal bounds of the IF 
expression pattern. Although it is usually found in cells of 
mesenchymal origin, vimentin may also be coexpressed with 
any of the other IFPs early in cellular differentiation. For 
example, in developing astrocytes, vimentin may be 
coexpressed with glial fibrillary acidic proteins 
(Schnitzer, J. et al. 1981; Tapscott, S.J., et al., 1981; 
Yen, S.-H., and K.L. Fields, 1981). During myogenesis, when 
the myoblast differentiates to the myotube, vimentin is 
down-regulated while the expression of desmin is up­
regulated (Sax et al., 1989; Bennett et al., 1979; 
Capetanaki et al., 1984; Holtzer et al., 1982). As in the 
case of the aforementioned breast cancer, various tumors of 
non-mesenchymal origin may coexpress vimentin (McGuire et 
al., 1989). The regulation of vimentin must therefore be 
complex and is under current investigation. 
Intermediate Filament Protein Structure 
IFPs have a common general secondary structure due to 
the highly conserved central rod domain. The a-helical rod 
is flanked by the N-terminus, commonly referred to as the 
head region, and by the C-terminus, commonly referred to as 
the tail region. 
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The head region accounts for most of the deviations in 
amino acid sequence between IFPs and between species. 
Although not quite as diverse, the tail region also exhibits 
little similarity between IFPs and between species. The 
central rod, the region with the most conservation, has a 
common quasi-repeating heptad of amino acids, delineated a­
b-c-d-e-f-g. Positions a and d are usually apolar residues 
while b,c,e and g are usually polar (Zehner et al., 1986; 
Ngai et al., 1990). This primary sequence allows the IFP 
subunits to wrap around each other, forming a basis for the 
coiled-coil structure characteristic of IFPs. 
Intermediate Filament Protein Assembly 
The first level of assembly is the formation of dimers. 
Dimers of the IFPs are formed by the coiled-coil 
interactions between the �-helical rod portions. The 
hydrophobic short-chain amino acids at positions a and d of 
the heptad repeat allow the chains to pack close together in 
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forming the dimer. These interactions are coordinated by the 
flanking head and tail regions which are thought to wrap 
around and stabilize dimer formation. Next, the dimers are 
paired in an anti-parallel fashion to form a tetramer, 
called a protofilament. Due to the anti-parallel pairing, 
the protofilaments are nonpolarized (Ngai et al., 1990) 
At the next step of assembly, protofilaments are 
thought to form an axially staggered array called a 
protofibril. Each fibril is equivalent to two 
protofilaments. The final 11 nm-diameter filament is formed 
by the association of four protofilaments. 
In instances where vimentin is co-expressed with other 
IFPs, it is not uncommon to find random heteropolymers. 
Although it has been demonstrated that IFPs will 
spontaneously polymerize in vitro, a simple self-assembly 
mechanism is highly unlikely since de novo assembly has been 
disproved (Ngai et al., 1990). Based on the observation that 
newly synthesized vimentin is incorporated into preexisting 
filaments, Ngai et al. has proposed a directed self-assembly 
scheme. According to this theory, assembly-competent regions 
within filaments are established or maintained to allow free 
subunits to assemble and elongate the filaments (Ngai et 
al., 1990). This theory is currently supported by the 
observation that vimentin subunits will insert at various 
discreet loci in the cytoplasm (Coleman and Lazarides, 
1992) . 
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Presently, there are over thirty different IFPs, and 
new members are still being isolated. For the most part, 
each IFP arises from its own unique gene: there is only one 
known example of differential splicing giving rise to more 
than one type of IF. Therefore, differential gene expression 
patterns must have evolved coincident with IFP divergence. 
Based on this, the regulation of eukaryotic gene 
transcription is important to determining which IFP is found 
in a particular cell type. 
Eukaryotic Transcription 
In general, transcription initiation of an eukaryotic 
gene requires several components. First, three types of 
eukaryotic polymerases exist. RNA polymerase II (pol II) is 
responsible for transcribing protein-coding genes, such as 
the IFP multi-gene family, and consists of 10 plus or minus 
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2 subunits. Pol II must be properly aligned at the promoter 
to correctly initiate transcription. The complex which forms 
to assure this alignment contains many other factors which 
are currently under study. 
The first step in forming the committed complex is the 
binding of transcription factor II D (TFIID) to the TATA box 
in the promoter. TFIID is a complex of proteins itself. It 
consists of the TATA-binding protein (TBP) and a host of 
TBP-associated factors (TAFs) . The TBP is sufficient to bind 
to the TATA box and initiate binding of other TFs, but the 
TAFs confer the transcription regulation by other factors. 
After TFIID binds, TFIIB binds and in turn binds TFIIF 
and pol II. Since pol II does not have the inherent ability 
to bind to the promoter itself, TFIIF is associated with pol 
II to facilitate binding. Although the complex now formed is 
stable, TFIIE,TFIIH, and TFIIJ also bind to the complex. 
TFIIE is needed to recruit TFIIH, which in turn 
phosphorylates the carboxy-terminal domain of pol II. It may 
be that this event signals promoter clearance and turns the 
initiation complex into an elongation complex, although 
there is still some controversy surrounding this ATP energy 
requirement (Buratowski, 1994i Drapkin et al., 1994). What 
has been observed is that phosphorylated pol II will not 
associate with TBP although the non-phosphorylated pol II 
will (Usheva et al., 1992). 
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Another factor whose purpose is not completely 
understood yet is that of TFIIA. This factor appears to bind 
early in formation of the complex to TFIID. The function of 
TFIIA has been postulated to be the inhibition of the action 
of various repressors on the forming transcription complex. 
By directly binding with the TBP, TFIIA may block the 
effects of these repressors and allow the other required TFs 
to associate. Again, this is still under investigation. 
Eukaryotic Transcription Regulation 
Several cis-acting elements have been characterized 
that influence transcription of eukaryotic genes. These 
include the promoter elements, enhancers, repressors, and 
anti-repressors. 
Promoters 
Promoters are responsible for the basal level of 
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transcription of a gene. For eukaryotic genes, they must 
include a sequence to which pol II can associate and thereby 
allow transcription to ensue. This is typically referred to 
as the TATA box. Located about 30 base pairs upstream of +1, 
the transcription start site, the TATA box is recognized by 
the TBP (see above) . It is here that the transcription 
machinery assembles and is properly aligned and the DNA is 
unwound. 
Promoters have also been described that contain no TATA 
box or show poor homology to its consensus sequence. In 
these cases, other cis-elements assume the role of the TATA 
box. Initiator sequences (INRs) overlap the transcriptional 
start site. INRs do not necessarily show homology across 
genes and therefore function through various trans-acting 
factors. The proposed model incorporates an INR-binding 
protein which serves the initial role of TBP in DNA binding 
(Hernandez, 1993). The factors that normally bind the TATA 
box then enter the complex. TBP has been observed to still 
bind, allbeit weakly, to the -30 region in the absence of 
the TATA box (Wiley et al., 1992); therefore, positioning 
would be correct but the efficiency of TBP binding would be 
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severely compromised. 
The promoter region may also contain a CAAT box, which 
binds a CAAT box transcription factor (CTF), and one or more 
GC boxes, which bind a protein known as Sp1. The CAAT box is 
located between -60 and -80 base pairs upstream of the 
transcription start site +1, and, although it is not 
palindromic, it may occur in either orientation. In the case 
of the GC/Sp1 complex, interaction has been observed with 
TBP. TAF-110 has been shown to bind to Sp1, thus bridging it 
to the TBP (Hoey et al., 1993; Hernandez, 1993). Many of the 
TATA-less promoters do contain one or multiple GC boxes, 
which greatly enhance transcription. Together these promoter 
elements determine the RNA polymerase specificity and the 
basal level of transcription. 
Enhancers 
Enhancers are defined by their ability to promote 
transcription in association with a promoter and function in 
a position- and orientation-independent manner. They have 
been identified thousands of base pairs away from the 
transcription start site, within introns of genes, and at 
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the 3'-ends of genes. The question of exactly how enhancers 
act remains unanswered. One possibility is that the enhancer 
sequence is recognized by a transcription factor that in 
turn may stimulate pol II to bind to the promoter region. 
The other thought is that the enhancer plus its 
transcription factor may interfere with the histone 
packaging of the DNA or cause a conformational change in the 
DNA such that it is now exposed and pol II is able to bind. 
In actuality, enhancers probably act in some combination of 
these proposed mechanisms (Voet and Voet, 1990). 
Repressors 
Like enhancers, repressors function in association with 
a promoter and in a position- and orientation-independent 
manner. Because repressors, also known as silencers, act at 
the level of the promoter, there are many points at which 
the effect may occur. Silencers may block binding of one of 
the transcription factors or pol II, or they may inhibit the 
actual start of transcription. On a more global scale of 
repression, compaction of DNA inhibits transcription 
greatly. Relatively little is known about this mode of 
regulation in terms of clearcut examples at the various 
steps, but progress is being made to understand where 
exactly the control is exerted (Herschbach and Johnson, 
1993) . 
Antirepressors 
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Antirepressors are a novel mode of regulation (Croston 
et al., 1991; Stover and Zehner, 1992). Like their 
counterparts, antirepressors appear to function in a 
position- and orientation-independent fashion. Genes 
containing these antirepressor, or antisilencer, sequences 
have taken regulation to another level. Their purpose is to 
override the silencing effects of the silencer elements. As 
a result, transcription rates have been observed to 
increase. Again, though, antisilencers by themselves will 
not enhance transcription: silencer elements must be present 
for the effect to be observed. 
Regulation of Chicken Vimentin 
The chicken vimentin gene has been previously isolated 
(Zehner and Paterson, 1983) and sequenced (Zehner et al., 
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1987). To date, regulation of transcription of the chicken 
vimentin gene has been found to include all four regions as 
depicted in Figure 1. Comparable elements in the human gene 
are also shown. The gene is present as a single copy in the 
chicken genome but yields two classes of mRNAs due to the 
utilization of different polyadenylation sites in the 3' ­
end. Covering 8.5 kb of DNA, the gene contains 9 exons. When 
compared with the hamster vimentin gene, both exon size and 
position are conserved (Zehner et al., 1987). Sequences 
required for the regulation of vimentin gene expression are 
found localized to the 5'-end (Sax et al., 1988; Sax et al., 
1989) . 
The vimentin promoter contains a relatively poor 
sequence homology to the consensus TATA box, yet this 
variant is functional in the globin gene. Within the 
promotor region, however, lie five GC boxes and a CAAT box. 
The CAAT box is unique in that it lies on the noncoding 
strand in the reverse orientation with respect to the gene. 
The GC boxes, which are known to increase transcription 
rates through binding the transcription factor Sp1, flank 
the CAAT box on either side. At least three of the five GC 
14 
Figure 1: Model of the regulatory elements of the chicken 
and human vimentin gene. This model is based on the 
isolation and characterization of various cis-acting 
elements found within the 5'-end of the vimentin gene. The 
human antisilencer element (ASE) has not yet been isolated 
but shows sequence homology and has been characterized with 
its APl sites. 
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sequences have been shown to actively interact with Spl (Sax 
et al., 1988). As a whole, this region, termed the proximal 
promoter element (PPE), is thought to be responsible for the 
basal levels of vimentin expression. 
Moving along the 5'-end in a linear fashion, the next 
region contains a silencer element (SE#l) flanked by an 
enhancer region on either side. The first enhancer element, 
referred to as proximal enhancer element 1 (PEEl), is 19 bp 
long and was shown to increase activity about four fold. The 
other element, termed PEE2 and located downstream of SE#l, 
is 19 bp in length and only increases activity about two 
fold. Both PEEs were observed to bind a protein similar in 
weight and binding specificity to the protein which binds 
the three SEs (Perkins et al., unpublished data). 
The first silencer element identified and characterized 
was SE#3, approximately 567 bp upstream from the 
transcription start site. This 40 bp long segment of DNA was 
observed to bind an approximately 90 kDa protein, which is 
currently being isolated. The silencer element protein (SEP) 
was demonstrated not to be Spl, although the two proteins 
are similar in size (Farrell et al., 1990). In addition to 
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the 90 kDa SEP, a 54 kDa protein was observed to associate 
with the SE and SEP. The 54 kDa protein is currently 
believed to aid in the binding of the SEP to the SE, but 
this has not yet been confirmed. By sequence homology, SE#1 
and SE#2 were later identified and synthesized. Both were 
shown to also bind the same 90 kDa protein as SE#3. In 
addition, when the relative abilities to repress 
transcription were measured, SE#1 was found to be the 
strongest. It effected a 75% reduction while SE#2 and SE#3 
were each observed to cause approximately a 50% reduction. 
When all three SEs were taken in conjunction, a 98% 
reduction over the PPE was observed (Garzon and Zehner, 
1994). Additional SE(s) have been postulated to exist in the 
region -607 to -1612, but nothing has been isolated yet. 
The last element characterized thus far is an 
antisilencer element (ASE) whose purpose is to override the 
negative effects of the SEs. This 75 bp fragment was shown 
to bind an approximately 120 kDa protein that is currently 
being isolated and sequenced. It was demonstrated to restore 
transcription levels to 100% when associated with the SEs 
(Stover and Zehner, 1992). Moreover, the FGF induction of 
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the vimentin gene appears to work specifically through this 
element and its factors(Carey and Zehner, unpublished data). 
A comparison of the DNA sequence of the various chicken and 
human SE, PEE, and ASE elements is shown in Figure 2. 
When tandem AP-1 sites were recognized as enhancers in 
the human vimentin gene (Rittling et al., 1989), a search 
was made to look for homologous sequences in the chicken 
vimentin gene. AP-1 is a jun-fos binding site which acts as 
an enhancer. Although two AP-1 sites have also been 
identified in the ASE region, the first one has been shown 
not to confer any antisilencing effects over the three SEs 
(Stover and Zehner, 1992). Another unique negative element 
has been discovered upstream of the ASE, in the region 
between -1612 and -1635. The second AP-1 site, located 
upstream of this element, has been shown to override the 
effects of the nearby negative element. This AP-1 site was 
shown to be serum inducible as well as TGF-� and phorbol 
ester TPA inducible (Carey and Zehner, unpublished data). 
In summary, the regulation of vimentin expression is a 
complex combination of interactions between several cis­
elements and trans-acting factors. Much work is being done 
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Figure 2: Comparison of chicken and human sequences. The DNA 
sequences for the silencer elements (SE) , the proximal 
enhancer elements (PEE) and the antisilencer elements (ASE) 
show strong homology. Both the chicken and human SE and ASE 
have been shown to bind the same SEP and ASEP, respectively. 
COMPARISON OF CHICKEN AND HUMAN 
SEQUENCES 
Chicken SE#l AGGAGCG (X) s GGAGCA 
Chicken SE#3 AGGAGCG (X) 9 GaAGCA 
Human SE gGGtcCG (X) 4 GcAcCA 
Chicken PEEl AGGgGCG (X) 3 GGcGCc 
Chicken PEE2 AGGgaCG 
Human PEEl AGGAagG (X) 2 cGAGgc 
Human PEE2 AGGgGCG (X) 2 GGAGgA 
(rev)Chicken ASE -1596GCTCTTGGCCACC-1608 
Human ASE _881GCTCTTGtCCcCC_869 
20 
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to elucidate the various controls. Because the vimentin gene 
structure is highly conserved across species (Figure 1), it 
is possible to study the regulation of the chicken gene in 
human cells such as breast cancer cell lines as well. As 
will be discussed next, two established cancer cell lines 
were isolated that differed in their expression pattern of 
vimentin. 
Breast Cancer 
According to the American Cancer Society's Cancer Facts 
& Figures 1993, breast cancer is the second major cause of 
cancer deaths in women. For noninvasive tumors, the five-
year survival rate nears 100% while in cases of distant 
metastases, the survival rate is only about 18%. Breast 
cancer is a general term for a whole host of complex tumors 
affecting the mammary gland epithelium. Some tumors are 
aggressive and metastatic while others are not nearly as 
invasive. MDA-MB-231, henceforth referred to as MDA, 
represents one of the cancers with the poorest prognosis due 
to its invasive nature. MCF-7 on the other hand has a 
relatively good prognosis as it is nonmetastatic. Clues to 
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differences in their behaviors lie in the expression pattern 
of various proteins. 
Though it is still not clear exactly which mutation(s) 
is responsible for triggering tumor progression, evidence 
points towards an accumulation of mutations. Some 
researchers speculate that it may take as many as four or 
five before the phenotype presents (Fearon and Vogelstein, 
1990). At the same time, though, a single mutation may be 
enough to alter growth patterns and lead to mild 
manifestations of a diseased state (Edwards, 1993). Whatever 
the cause, the effect is to alter the machinery governing 
the growth and differentiation of the cell. 
Vimentin Expression in Breast Cancer 
As an IFP, vimentin shows a unique expression pattern. 
Vimentin is normally expressed in cells of mesenchymal 
origin, therefore being first synthesized in the very early 
steps of embryogenesis. It is the IFP type found in many 
established cell lines in tissue culture, is cell cycle 
regulated, and is induced by serum phorbol esters and 
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several growth factors, ie. PDGF, TGF-�, and FGF. Because of 
this expression pattern, it has been suggested that vimentin 
is the preferred type of IFP found in the freely dividing, 
highly proliferative cell. Moreover, vimentin expression has 
been observed in certain poorly-differentiated breast 
carcinomas (Raymond and Leong, 1989). It has been suggested 
that these carcinomas may represent cells which have de­
differentiated and have reverted back to their embryonic 
forms because they lose cell-to-cell contact inhibition 
which results in metastasis (Ramaekers et al., 1983; Gould, 
1986). Therefore, vimentin could be used as a prognostic 
marker for metastatic breast carcinomas (Raymond and Leong, 
1989) . 
Vimentin has clearly been demonstrated to have an 
altered expression pattern in the metastatic MDA versus the 
nonmetastatic MCF-7 cell(Sommers et al., 1989; Stover et 
al. , 1994). By Northern analysis, no vimentin mRNA is 
detectable in the MCF-7 cell line while it is abundant in 
the MDA line (Figure 3A) . This agrees with the 
aforementioned observation that vimentin expression 
correlates with metastasis. 
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In addition, to examine differences in vimentin 
regulation between the two cancer cell lines, a Southwestern 
showing the binding activity of both the SEP and ASEP was 
analyzed (Figure 3B). In the case of the SE#3, the MCF-7 
cells showed maximal binding activity while the MDA cells 
showed no binding of the SEP. The opposite pattern was seen 
with the ASEP: the MDA line showed maximal binding while the 
MCF-7 line exhibited only about 60% maximal binding 
activity. Both binding patterns confirm the vimentin RNA 
expression pattern observed in the Northern blot. 
To explore the possible correlation between metastasis 
and vimentin expression, it was necessary to identify two 
breast cancer cell lines which differed in their vimentin 
expression pattern. Transformed culture cells are typically 
marked by three traits: a decrease in growth factor 
requirements, a loss of anchorage dependence, and a loss of 
contact inhibition. It has been found that most eukaryotic 
cells introduced into culture will synthesize vimentin, 
regardless of their tissue origin (Pieper et al., 1992) 
This is probably due to a combination of the effects of 
serum and/or growth factors present in the media and the 
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Figure 3: Northern and Southwestern blot analyses of two 
different breast cancer cell lines, MCF-7 and MDA-MB-231. A, 
total RNA (3 �g) was analyzed and hybridized with a 32P­
labeled human vimentin eDNA as described in Stover et al., 
1994. B, crude nuclear extracts (50 �g) from both breast 
cancer cell lines were hybridized with 32P-labeled SE and 
ASE of equal radiospecific activity and quantitated using 
scanning densitometry as described in Stover et al., 1994. 
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tendency of such cells to revert and re-enter the cell 
cycle. Therefore, it was imperative to find two established 
breast cancer cell lines which maintained their vimentin 
expression pattern in culture similar to that of the primary 
tumor from which they were derived. Presumably these cells 
were derived from tumors at different stages in progression 
to the metastatic state. Since expression exists in one line 
but not the other, it was concluded that these would be 
appropriate for study of the differential regulation of the 
vimentin gene. 
Rationale 
The purpose for this study was to examine the various 
5'-end regulatory regions of the chicken vimentin gene for 
their activity in human breast cancer cell lines with 
opposite vimentin expression patterns. Activity from MDA 
cells, which express vimentin, were to be compared with MCF-
7 cells, which do not express vimentin. This study focused 
on the SE regions, whose human counterpart has been isolated 
and has been shown to bind the same SEP. Also, the human 
equivalent for the ASE has been found by sequence 
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comparisons and shows a match of 11 out of 13 bp. Because 
the chicken and human SEs and ASEs show such homology and 
bind the same proteins, transfecting the chicken vimentin 
regulatory regions into the breast cancer cell lines was 
deemed applicable. In addition, a transfection method that 
would effectively introduce the DNA constructs into the cell 
lines was also determined. 
MATERIALS AND METHODS 
Plasmid Preparation 
Plasmid constructs were previously synthesized as indicated 
(Sax et al., 1988; Farrell et al., 1990; Stover and Zehner, 
1992; Garzon and Zehner, 1994). The 5'-end content of plasmid 
preparations was verified using the appropriate restriction 
enzymes and visualized on an 8% polyacrylamide gel. 
Sequencing 
The plasmid construct containing SE#1 was verified by 
sequencing. The sample was run on an 8% polyacrylamide-7M urea 
sequencing gel, dried, and visualized on film with an enhancer 
screen. 
Cell Culture, DNA Transfections, and CAT Assays 
MDA-MB-231 cells (Thompson et al., 1992) were obtained 
indirectly from the ATCC (Rockville, MD) through Dr. Eric 
Westin's lab at the Medical College of Virginia (MDA-1). The 
cells were maintained in Dulbecco's modified Eagle's medium 
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(DMEM) supplemented with 10% fetal calf serum (FCS) and 0.1% 
ampicillin. MDA-MB-231 (MDA-2) and MCF-7 cells were also 
obtained indirectly from ATCC through Dr. Mary Hendrix's lab 
at the Pediatric Research Institute, St. Louis University, St. 
Louis, MO, and were maintained in RPMI 1640 medium 
supplemented with 10% FCS and 0.1% gentamicin. 
All cell types were transfected using the calcium 
phosphate coprecipitation technique. For each set of 
transfections, p8CAT was used as a control and pcV-160 was 
included to measure the basal level of transcription 
determined by the promoter. Twenty-four hours prior to 
transfection, cells were plated at a density of 8 x 105 cells 
per 100 mm tissue culture dish in the respective medium. 15 �g 
of plasmid DNA were introduced to each dish. The media was 
removed from the dishes, and the cells were washed with 4 ml 
of fresh media. The DNA-calcium phosphate precipitate was then 
added dropwise over the cells. The plates were allowed to sit 
at 25° C for 20 min with gentle shaking every 5 min. Four ml 
of media was gently added, and the cells were incubated 
overnight at 37° C. After 24 h, the media was discarded, and 
the cells were gently washed with 4 ml of fresh media. Three 
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ml of a 15% glycerol solution were introduced, and the plates 
were incubated at 37° C for 4 min. The glycerol was then 
discarded, and the cells were again washed with 4 ml of fresh 
media. Fresh media ( 10 ml) was added, and the cells were 
incubated overnight at 37° C. After 24 h, cells were washed 
and harvested in phosphate buffered saline, pelleted, and 
resuspended in 100 �l of 0.25 M Tris. Protein was extracted 
from the cells by a freeze-thaw cycle repeated three times. 
The tubes were then centrifuged at 15,000 rpm for 8 min at 4° 
C. The supernatants were collected, and protein concentrations 
were determined by the Lowry method (Lowry et al.,1951). The 
remaining protein was stored overnight at -20° C. 
The chloramphenicol acetyltransferase (CAT) assay was 
performed as described by Gorman et al. (1982). Results were 
quantified by excising the radioactive spots from the silica 
plates and using a liquid scintillation counter to determine 
the 14C content. The dpms obtained from the counter were then 
converted to pm of acetylated CAT. From this, activity was 
calculated as the percent acetylated chloramphenicol from the 
various constructs versus acetylated chloramphenicol from pcV-
160. Promoter-driven activity was corrected for using 
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background levels of the p8CAT vector promoterless construct. 
The values reported are the average of at least six separate 
transfections and error bars were calculated using the 
standard error of the mean (SEM) . 
Nude Mouse Assay and Invasive Assay 
MDA-MB-231 cells obtained from Dr. Eric Westin were checked by 
injection into nude mice to determine metastatic potential. 2 
x 106 cells were injected into the mammary fat pad. The mice 
were sacrificed approximately four weeks later, and the 
internal organs were retrieved for histological evaluation. 
MDA-MB-231 cells obtained from Dr. Mary Hendrix were 
tested for metastasis by a modified Boyden chamber 
chemoinvasive assay (personal communication) 
RESULTS 
DNA Transfections 
The calcium phosphate coprecipitation technique was 
determined to be an effective mode of transfection in both the 
MDA and MCF-7 cell lines and was subsequently used for all 
trials. It was noted that the MDA-1 cells from Dr. Eric Westin 
(MCV/VCU) were grown in DMEM while the MDA-2 and MCF-7 cells 
from Dr. Mary Hendrix (St. Louis University) were grown in 
RPMI-1640. Upon introducing the CaP04 solution to the cells 
grown in RPMI-1640, it was observed that a white precipitate 
formed. Also, it was observed that many of the cells had 
subsequently lysed. 
MDA Data 
The first cells examined were those obtained from Dr. 
Westin's lab (MCV/VCU). As can be seen in Figure 4, 
transcriptional activity in all cases is reported as the 
percent pcV-160 activity, which is the basal promoter 
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Figure 4: Transient transfections of various chicken vimentin 
5'-end CAT constructs in MDA-MB-231 cells (1). Transfection 
was accomplished using the calcium phosphate coprecipitation 
technique as described in Materials and Methods. Values 
reported are relative to the basal promoter pcV-160 activity, 
and error bars were calculated using the SEM. 
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activity. Construct pcV-567 showed only about 25% activity 
relative to the basal promoter. Since this element contains 
the first two SEs, the 75% repression seen was not surprising. 
What was surprising was the activity of pcV-607, whose 
sequence merely includes that of SE#3. Rather than reducing 
activity further, inclusion of the third SE showed about the 
same activity or maybe slightly more activity than pcV-567. 
Remembering that these MDA cells do express vimentin, it may 
be here that part of the regulation of vimentin expression is 
affected. Taken individually, both SE#l and SE#3 fused 
directly to pcV-160 showed quite different activity levels. 
SE#l appeared to repress activity by about 75% while SE#3 
repressed very little, if at all. When the ASE was examined, 
it also showed very little activity. Exhibiting only 25% of 
the total activity, the ASE does not appear to be the only 
factor responsible for vimentin expression in these cells. 
The second line of MDA cells was examined in comparison 
to both the previous MDA cells and the MCF-7 cells. Again, in 
Figure 5, the data reported is relative to the basal promoter 
activity. Constructs pcV-567 and pcV-607 showed little 
difference in their activity. This is in agreement with the 
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Figure 5: Transient transfections of various chicken vimentin 
5'-end CAT constructs in MDA-MB-231 cells (2). Transfection 
was accomplished using the calcium phosphate coprecipitation 
technique as described in Materials and Methods. Values 
reported are relative to the basal promoter pcV-160 activity, 
and error bars were calculated using the SEM. 
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observations from the first set of cells. The same is true for 
SE#1 and SE#3 fused directly to the promoter. SE#1 shows only 
about 25% activity, while SE#3 shows about 75-80% activity. On 
the other hand, construct pcV-1693, including the ASE and 
distal AP1 site, appeared to be functioning to a greater 
extent, yielding activity of approximately 70%. 
MCF-7 Data 
The results of DNA transfections into the MCF-7 cells are 
shown in Figure 6. Construct pcV-567 showed an activity of 
about 25%, similar to that observed for both sets of MDA. On 
the other hand, pcV-607 showed activity of about 50%. This 
appears to demonstrate that inclusion of SE#3 actually 
increases activity rather than repressing it. SE#1 fused to 
the promoter showed activity of only 50%, which agrees with 
earlier studies (Garzon and Zehner, 1994). SE#3 fused to the 
promoter essentially yielded full activity of 100%. It would 
appear that this SE is not functioning in the MCF-7 cells, 
which does not agree with the fact that these cells do not 
express vimentin. The ASE showed only about 50% activity, 
which theoretically may not be sufficient to overcome the 
silencing effects. 
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Figure 6: Transient transfection of various chicken vimentin 
5'-end CAT constructs in MCF-7 cells. Transfection was 
accomplished using the calcium phosphate coprecipitation 
technique as described in Materials and Methods. Values 
reported are relative to the basal promoter pcV-160 activity, 
and error bars were calculated using the SEM. 
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Nude Mouse Assay 
All four of the mice injected with the MDA cells from Dr. 
Eric Westin developed macroscopic metastases. Tumors were 
directly observed in the liver, spleen, mesenteric lymph 
nodes, lungs, kidneys, intestines, and the ovaries. 
DISCUSSION 
The purpose of this study was two-fold. The first 
objective was to determine a transfection protocol that would 
effectively introduce chimeric DNA into the two cancer cell 
lines. The second objective was to study possible regulatory 
differences between the two cancer cell lines by comparing the 
resultant CAT activity from various 5'-end constructs. The MDA 
and MCF-7 cell lines exhibit opposite expression patterns of 
vimentin mRNA and were therefore chosen to try to determine 
where in the regulation of vimentin gene transcription the 
difference in expression arises. As will be discussed, several 
possibilities exist to explain the observed results. 
The first step in the study was to determine a 
transfection protocol that would effectively introduce the DNA 
into both cell lines. Past experience in this laboratory with 
DNA transfections has shown the CaP� coprecipitation 
technique to be the most effective. This technique was 
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therefore attempted first, and the test trial showed CAT 
activity, which meant that the DNA was indeed being taken up 
and expressed by the cells. Throughout the study, the CaP04 
technique was then used to introduce the various gene 
constructs into the cells. 
One noted observation was the appearance of a white 
precipitate that formed upon mixing of the CaP04-DNA solution 
and the RPMI media. Twenty-four hours later, many of the cells 
appeared to have lysed. CAT activity was still obtained, so 
the cells that survived were still able to take up and express 
the transfected DNA. The stocks of DNA constructs were 
determined not to be the cause, because the precipitate formed 
only when the CaP04 solution and the RPMI media were mixed in 
a dish. DMEM did not show any adverse reactions like the RPMI. 
The only apparent difference in RPMI and DMEM is that RPMI 
contains inositol. The DMEM actually contains more CaC03, 
which we originally thought might be the source of the 
precipitate. For future studies, the cell lines can be 
transfected by the CaP04 coprecipitation technique, but they 
will need to first be conditioned to another medium, 
preferentially DMEM since that did not show any evidence of 
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side reactions. 
Part two of this study was to examine the expression 
patterns observed upon introduction of the various regulatory 
regions fused to the CAT reporter gene into the metastatic and 
nonmetastatic cell lines. Stover et al. determined that MDA 
cells do express vimentin while MCF-7 cells do not. From a 
Southwestern blot, Stover et al. showed 100% binding activity 
of the SEP to SE#3 in MCF-7 cells while almost no SEP bound to 
SE#3 in MDA cells. When they examined the ASE, they found 100% 
binding of the ASEP in MDA cells while only about 60% binding 
of the ASEP was observed in MCF-7 cells. The differences in 
these binding activities supported the observed expression 
patterns of vimentin in these two cell lines; therefore, 
constructs containing these regulatory elements were used for 
the study. 
p8CAT, a derivative of pEMBL8 (Dente et al., 1983), 
contains the bacterial CAT gene and an ampicillin resistance 
gene. Expression of vimentin was therefore inferred from the 
measured CAT expression. In all cases, the activity of the 
constructs was reported relative to the pcV-160 construct, 
which contains the basal promotor element of the vimentin 
46 
gene. 
MDA cells obtained from Dr. Eric Westin (MCV/VCU) were 
tested first, but since the MDA cells obtained from Dr. Mary 
Hendrix exhibited a similar activity profile, they will be 
discussed simultaneously. SE#3, which was used in the binding 
studies of the SEP, showed little, if any, repression. This 
agrees with the previous data that the SEP does not bind in 
the MDA cells and therefore vimentin is expressed. SE#l, on 
the other hand, showed 75-80% repression of activity and 
appeared to be functioning. In support of these observations, 
pcV-567 and pcV-607 showed similar patterns. Construct pcV-567 
contains SE#l, SE#2, and other negative regulatory elements 
which have not yet been fully identified or characterized. 
This particular construct also showed about a 75% repression 
in activity. By adding on SE#3 in pcV-607, though, no 
additional repression activity was observed. This meant that 
SE#3 was not functional in MDA cells. The discrepancy was in 
SE#l activity: it appeared to be functional, although we know 
that MDA cells do not express vimentin. One explanation for 
this is that the SEP is mutated in such a way so that it may 
still be able to bind to SE#l but no longer to SE#3. From 
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Figure 3, one can see that the SE sequences are not identical, 
which may affect binding ability. SE#l may be the preferred 
sequence and thus bind the protein more tightly. When the 
protein is mutated, the binding to SE#3, which is presumably 
weaker to begin with, may be abolished and thereby inactivate 
SE#3. The other possibility is that the 54 kDa protein, 
thought to be required for functional silencer protein 
binding, may be mutated and affecting SEP binding. Since very 
little is known about the role of the 54 kDa protein at this 
time, it is difficult to assess the importance of this protein 
to SEP function. On the other hand, a combination of mutations 
in both proteins may contribute to aberrant vimentin 
expression. 
In studying the ASE, activity was only restored about 25% 
in the first set of MDA cells. Previous studies in mouse L-
cells have shown that the ASE can restore about 80% of the 
activity, but the activity we observed in the MDA cells was 
substantially lower. As was previously determined, the ASE 
only functions in the presence of the SEs. What is not clear 
is exactly how this ASE works. If the SEP must be bound to the 
three SEs in order to initiate binding of the ASEP to the ASE, 
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then having only one SEP bound to SE#1 may not be enough to 
fully activate the ASE in overriding SE#1. In other words, the 
conformation of the DNA and/or protein-protein interactions 
may play a role in how the ASE acts. Further studies are 
needed to determine how the ASE acts in vivo. However, in 
analyzing the results from the second set of MDA cells, the 
ASE appeared to be functioning. The difference between the ASE 
constructs used in MDA 1 and MDA 2 is about 80 bp. Included in 
the 80 bp is a second AP-1 site. At least in the case of human 
vimentin, this second AP-1 site was shown to have a 
significant antisilencing effect (Rittling et al., 1989). In 
conclusion, the second AP-1 site may play a crucial role in 
establishing the full antisilencing effect in the MDA cell 
line such that vimentin is highly expressed. 
The profile observed for the MCF-7 cell line is 
indicative that vimentin's regulatory elements are still 
present. Since these cells do not normally express vimentin, 
though, the gene may be under more global mechanisms of 
control such as methylation and DNA condensation. The 
similarity in the MCF-7 versus the MDA profiles suggests that 
the trans-acting factors are still functional. For the native 
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gene to be turned on, other events must occur before the 
trans-acting factors may interact with the 
elements. 
cis-acting 
In summary, the results observed for SE#3 substantiated 
the earlier findings of Stover et al. that functional 
SE#3:protein binding was not occurring in the metastatic MDA 
cell line. Surprisingly, SE#1 appeared to be functional. As 
for the ASE, the first ASE construct did not appear to 
function as expected, but this was probably due to the absence 
of the distal AP-1 site. The fact that the second AP-1 site in 
human vimentin has been shown to be critical for antisilencing 
activity further supports this. When the second chicken AP-1 
site was included, the antisilencing effect was restored and 
again substantiated the earlier findings of Stover et al. The 
results from the MCF-7 cell line suggest that all regulatory 
factors are present and functional, but the native gene is 
probably under more global mechanisms of control which 
completely repress gene transcription. The key to 
understanding the differences in regulation between these two 
cell lines will lie in understanding the SE and the ASE. 
Further characterization of how the SEP and 54 kDa protein 
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interact and how the ASEP is able to override the SE effects 
will provide the clues as to how these regulatory differences 
affect gene transcription. 
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